Neal E Ready MD

Oncology•Durham, NC

Professor, Medicine, Duke University School of Medicine

Join to View Full Profile

4101 N Roxboro StDurham, NC 27704
Phone+1 919-684-8111

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1986 - 1989
Vanderbilt University School of MedicineClass of 1986

Certifications & Licensure

NC State Medical License 2006 - 2025
RI State Medical License 1988 - 2006
MA State Medical License 1994 - 2003
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013

Clinical Trials

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2002 May 01
Completed
Phase 2
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15
Completed
Phase 1, Phase 2
Study of Sorafenib/Cetuximab in Head and Neck Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Neoadjuvant Pembrolizumab Start of enrollment: 2017 Jan 01
Active, not recruiting
Phase 2
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Start of enrollment: 2016 Dec 01
Terminated
Phase 2
TOP 2301: Neoadjuvant Chemo for NSCLC Start of enrollment: 2025 Mar 17
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Tumor-Associated Molecules Lead the Way to New Therapies for Small Cell Lung Cancer.
Cameron Oswalt, Neal Ready
JCO Oncology Practice. 2025-04-02
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah
Journal for Immunotherapy of Cancer. 2025-02-04
2 citations
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02

Press Mentions

Targeting Innovation in Small Cell Lung CancerNovember 29th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member